Crystal commemorative marking the initial public offering of Australian biotech firm Chimeric Therapeutics. The firm is developing a class of cell therapy drugs for the treatment of cancer.
(21ALJ210)Crystal commemorative marking the initial public offering of Australian biotech firm Chimeric Therapeutics. The firm is developing a class of cell therapy drugs for the treatment of cancer.
(21ALJ210)Lucite tombstone commemorating crossover funding for AbSci, a Vancouver, Washington-based biotech firm.
(21ALJ163)Crystal deal tombstone celebrating the initial public offering of Arctic Bioscience. The Norwegian biotech firm makes use of bioactive marine compounds, including herring roe extracts.
(21LJW055)Custom financial tombstone commemorating an offering by Artelo Biosciences, a San Diego-based biopharmaceutical firm.
(20AJH203)Custom deal toy celebrating a follow-on public offering by Applied UV, a technology company employing narrow-range ultra violet light (UVC) to combat pathogens.
(20AJH232)Lucite tombstone celebrating Series A funding for Trailhead Biosystems. The Cleveland-based biotechnology company is focused on the application of machine-enabled technology.
(21ADH001)Lucite tombstone celebrating a private placement and concurrent global offering of shares by Calliditas Therapeutics. Joint bookrunners in the offering by the Swedish biotech firm were Citi, Jefferies, and Stifel.
(20ALJ348)Crystal deal toy commemorating the acquisition of Philadelphia-based Spark Therapeutics. The acquiring firm, Swiss pharmaceutical firm Roche, is headquartered in Basel.
(9ALJ621)Crystal deal toy, incorporating an interior, 3-D etching of Thor’s hammer, commemorating a private placement by pharmaceutical company Photocure ASA. Based in Oslo, Norway, Photocure specializes in photodynamic therapies that make use of light-activated drugs.
(20LJW163)